PORTFOLIO

Aegis Analytical Corporation

develops and markets manufacturing informatics, that helps high-end regulated manufacturers (i.e. pharmaceutical, biotechnology, medical device and food companies) to leverage their large investment in process control data and data acquisition systems to improve time to revenue for new products and yield quality from their existing plants.

Ganymed Pharmaceuticals AG

is developing monoclonal antibody therapeutics against solid tumors, where current therapies are poor and where there is an overriding medical need. GANYMED's pan cancer surface antigens are uniquely specific for cancer tissues and can be expected to show greater therapeutic efficacy and better safety allowing significant reduction in time to market. The Company's complementary drug development platforms are generating a sustainable pipeline of antigen targets and monoclonal antibody leads of unique cancer specificity.

Genomatix Software GmbH

offers software, databases and services aimed at understanding gene regulation at the molecular level representing a central part of systems biology. Genomatix’s multilayer integrative approach is a working implementation of systems biology principles enabling a better understanding of biological mechanisms under different conditions and stimuli in the biological context of your data.

Preventor µTBC GmbH

develops and commercialises innovative, compact and cost effective products in all areas of drug safety. The main objectives are to optimize the safety profile of drugs throughout the development pipeline, lower the attrition rates and, eventually, assist in offering innovative drugs to patients as quickly as possible. Preventor has developed and distributes the Drug Solubility Workstation SuperSol 1000.

vasopharm GmbH

develops innovative drugs and diagnostics to treat cardiovascular diseases by targeting endothelial dysfunction.

Vasopharm’s most advanced drug, VAS-203 for the treatment of traumatic brain injury has entered first clinical trials.

Venture Investors

Early Stage Fund III LP is a venture capital fund with a primary focus on high technology companies, spinning out of the University of Wisconsin, Madison, the fourth largest research institution of the USA. The portfolio includes three IPOs and one trade sale to date. Two further IPOs have already been filed for 2007. The fund is performing in the top quartile among its peers.